Pfizer Ltd
PFIZER NSE
Pfizer Ltd
HealthcareNSE: PFIZER BSE: 500680 Pharmaceuticals & Biotechnology
Key Fundamentals
SmallcapPharmaceuticalsHealthcareMarket Cap
₹21,363 Cr
Volatility
Moderate
P/E Ratio
28.69
EBITDA
₹855 Cr
Return on Equity
15.33%
Debt to Equity
0.01
Book Value
₹918.71
EPS
₹131.73
52W High
₹5,993
52W Low
₹4,396.7
Technical Indicators
Key Insights
Strengths
2- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 58.3%
Weaknesses
1- The company has delivered a poor sales growth of 2.39% over past five years.
Growth Rate
Revenue Growth
2.69% ↗
Net Income Growth
-6.44% ↘
Cash Flow Change
156.87% ↗
ROE
18.72% ↗
ROCE
14.12% ↗
EBITDA Margin (Avg.)
-15.08% ↘
Quarterly Results
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 573 | 531 | 575 | 540 | 547 | 563 | 589 | 538 | 592 | 603 | 642 | 645 | 629 |
| Expenses | 391 | 421 | 393 | 387 | 357 | 385 | 399 | 392 | 364 | 393 | 412 | 417 | 393 |
| Operating Profit | 182 | 111 | 183 | 153 | 189 | 177 | 189 | 146 | 228 | 210 | 230 | 228 | 236 |
| OPM % | 32% | 21% | 32% | 28% | 35% | 32% | 32% | 27% | 38% | 35% | 36% | 35% | 38% |
| Other Income | 12 | 33 | 36 | 44 | 75 | 42 | 43 | 43 | 217 | 67 | 42 | -20 | 50 |
| Interest | 3 | 3 | 3 | 3 | 7 | 2 | 2 | 2 | 3 | 3 | 2 | 2 | 2 |
| Depreciation | 26 | 16 | 15 | 18 | 14 | 15 | 15 | 15 | 16 | 14 | 14 | 14 | 15 |
| PBT | 165 | 126 | 201 | 176 | 244 | 203 | 215 | 172 | 426 | 260 | 255 | 192 | 269 |
| Tax % | 21% | 26% | 26% | 26% | 27% | 26% | 26% | 26% | 22% | 26% | 26% | 26% | 26% |
| Net Profit | 130 | 94 | 149 | 130 | 179 | 151 | 158 | 128 | 331 | 192 | 189 | 142 | 200 |
| EPS in Rs | 28.34 | 20.44 | 32.56 | 28.41 | 39.1 | 32.94 | 34.61 | 27.89 | 72.34 | 41.91 | 41.32 | 31 | 43.68 |
Profit & Loss
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,853 | 2,012 | 1,966 | 1,969 | 2,082 | 2,152 | 2,239 | 2,611 | 2,425 | 2,193 | 2,281 | 2,520 |
| Expenses | 1,438 | 1,579 | 1,616 | 1,468 | 1,516 | 1,578 | 1,526 | 1,775 | 1,616 | 1,555 | 1,540 | 1,616 |
| Operating Profit | 414 | 433 | 350 | 501 | 566 | 574 | 712 | 836 | 809 | 638 | 742 | 904 |
| OPM % | 22% | 22% | 18% | 25% | 27% | 27% | 32% | 32% | 33% | 29% | 33% | 36% |
| Other Income | 44 | 97 | 232 | 114 | 167 | 183 | 81 | 63 | 134 | 185 | 344 | 139 |
| Interest | 2 | 1 | 2 | 1 | 2 | 11 | 15 | 11 | 13 | 15 | 8 | 9 |
| Depreciation | 250 | 58 | 63 | 66 | 71 | 103 | 109 | 115 | 106 | 62 | 61 | 58 |
| PBT | 207 | 470 | 517 | 548 | 660 | 642 | 669 | 773 | 824 | 746 | 1,016 | 976 |
| Tax % | 66% | 35% | 35% | 34% | 35% | 21% | 26% | 21% | 24% | 26% | 24% | 26% |
| Net Profit | 70 | 305 | 337 | 360 | 429 | 509 | 498 | 613 | 624 | 551 | 768 | 722 |
| EPS in Rs | 15.26 | 66.67 | 73.62 | 78.71 | 93.79 | 111 | 109 | 134 | 136 | 121 | 168 | 158 |
| Div. Payout % | 82% | 22% | 27% | 25% | 24% | 297% | 32% | 26% | 29% | 29% | 98% | 48% |
Balance Sheet
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 46 | 46 | 46 | 46 | 46 | 46 | 46 | 46 | 46 | 46 | 46 | 46 |
| Reserves | 1,927 | 2,118 | 2,373 | 2,637 | 2,966 | 3,350 | 2,347 | 2,819 | 3,162 | 3,550 | 4,172 | 4,157 |
| Borrowings | 2 | 2 | 2 | 2 | 2 | 2 | 63 | 39 | 41 | 40 | 41 | 70 |
| Other Liabilities | 638 | 722 | 840 | 1,004 | 926 | 1,007 | 810 | 997 | 752 | 593 | 653 | 649 |
| Total Liabilities | 2,614 | 2,888 | 3,261 | 3,690 | 3,940 | 4,405 | 3,266 | 3,901 | 4,001 | 4,229 | 4,911 | 4,922 |
| Fixed Assets | 944 | 925 | 902 | 950 | 886 | 973 | 894 | 869 | 749 | 713 | 724 | 678 |
| CWIP | 13 | 3 | 15 | 1 | 0 | 1 | 3 | 1 | 8 | 0 | 8 | 20 |
| Investments | 43 | 37 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 1,614 | 1,923 | 2,343 | 2,739 | 3,054 | 3,432 | 2,369 | 3,030 | 3,244 | 3,516 | 4,180 | 4,224 |
| Total Assets | 2,614 | 2,888 | 3,261 | 3,690 | 3,940 | 4,405 | 3,266 | 3,901 | 4,001 | 4,229 | 4,911 | 4,922 |
Cash Flow
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 113 | 345 | 329 | 332 | 98 | 323 | 427 | 667 | 356 | 257 | 660 | 968 |
| Investing | 68 | -701 | -250 | -238 | 35 | 1,530 | -469 | -575 | -36 | 54 | -71 | -562 |
| Financing | -1 | -62 | -83 | -110 | -110 | -164 | -1,571 | -181 | -346 | -235 | -205 | -798 |
| Net Cash Flow | 181 | -417 | -3 | -17 | 23 | 1,690 | -1,613 | -88 | -26 | 75 | 383 | -392 |
| Free Cash Flow | 93 | 398 | 394 | 262 | 125 | 343 | 410 | 654 | 292 | 291 | 783 | 944 |
| CFO/OP | 62 | 120 | 146 | 105 | 59 | 93 | 89 | 107 | 81 | 64 | 110 | 105 |
Ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 32 | 26 | 20 | 29 | 30 | 29 | 18 | 20 | 23 | 31 | 31 | 26 |
| Inventory Days | 191 | 167 | 148 | 147 | 189 | 198 | 199 | 173 | 175 | 200 | 214 | 195 |
| Days Payable | 165 | 157 | 178 | 245 | 213 | 197 | 130 | 102 | 91 | 77 | 68 | 89 |
| Cash Conversion Cycle | 58 | 36 | -10 | -69 | 6 | 31 | 87 | 91 | 107 | 154 | 177 | 132 |
| Working Capital Days | 7 | -9 | -47 | -57 | -16 | -8 | 3 | -14 | 1 | 24 | 23 | 9 |
| ROCE % | 24% | 22% | 17% | 21% | 23% | 20% | 23% | 29% | 26% | 22% | 22% | 24% |
Documents
1
Board Meeting Intimation for Board Meeting To Consider And Approve The Financial Results For The Quarter And Year Ended March 31, 2026.
5 May - Board meets May 12, 2026 to approve Q4 and FY26 results, and consider dividend. 5 May - Board meets May 12, 2026 to approve Q4 and FY26 results, and consider dividend.
2
Intimation Pursuant To Regulation 30 Of SEBI LODR Regulations, 2015
24 Apr - Pfizer received FY23 income-tax demand of Rs 85.74 crore and penalty show-cause notice on April 23, 2026. 24 Apr - Pfizer received FY23 income-tax demand of Rs 85.74 crore and penalty show-cause notice on April 23, 2026.
3
Intimation Pursuant To Regulation 30 Of SEBI LODR Regulations, 2015
13h - Pfizer received FY23 income-tax demand of Rs 85.74 crore and penalty show-cause notice on April 23, 2026. 13h - Pfizer received FY23 income-tax demand of Rs 85.74 crore and penalty show-cause notice on April 23, 2026.
4
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
9 Apr - Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026 9 Apr - Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026
5
Announcement under Regulation 30 (LODR)-Newspaper Publication
8 Apr - Newspaper Advertisement - Special Window for Re - lodgement of transfer and Dematerialization of Physical Securities. 8 Apr - Newspaper Advertisement - Special Window for Re - lodgement of transfer and Dematerialization of Physical Securities.
Frequently Asked Questions about Pfizer Ltd
What does Pfizer Ltd do?
Pfizer Ltd is engaged in manufacturing, marketing, trading and export of pharmaceutical products. It manufactures products through its own facility and also has various independent contract/ third party manufacturers based across the country and sells its products through independent distributors...
Where is Pfizer Ltd (PFIZER) listed?
Pfizer Ltd is listed on the Indian stock exchanges. It is listed on NSE: PFIZER and BSE: 500680. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Pfizer Ltd belong to?
Pfizer Ltd operates in the Healthcare sector within the Pharmaceuticals & Biotechnology industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Pfizer Ltd?
Pfizer Ltd has a market capitalisation of approximately ₹21363.28 Cr. Based on this, it is classified as a Large Cap stock.
What is the PE ratio of Pfizer Ltd?
The Price-to-Earnings (PE) ratio of Pfizer Ltd is 28.69. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Pfizer Ltd?
Over the past 52 weeks, Pfizer Ltd has traded between a low of ₹4,396.7 and a high of ₹5,993. This range helps investors understand the stock's price volatility and recent trading levels.
Does Pfizer Ltd pay dividends?
Yes, Pfizer Ltd has a dividend yield of 1.68%. Dividend yield indicates the annual dividend income relative to the share price. A consistent dividend history can signal financial stability.
What is the Return on Equity (ROE) of Pfizer Ltd?
Pfizer Ltd has a Return on Equity (ROE) of 15.33%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Pfizer Ltd on Tapetide?
On Tapetide, you can view Pfizer Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.
Company Information
Pfizer Ltd is engaged in manufacturing, marketing, trading and export of pharmaceutical products. It manufactures products through its own facility and also has various independent contract/ third party manufacturers based across the country and sells its products through independent distributors primarily in India.[1] It is the 3rd largest multinational pharmaceutical company in India.[2]
Website pfizerindia.com
CEO Ms. Meenakshi Nevatia
Employees 1,598
Listed 1999-04-28
Face Value ₹ 10
Issued Size 4,57,47,732